Status:
COMPLETED
Assessment of Lung Inflammation With FDG PET/CT in COVID-19
Lead Sponsor:
Centre Hospitalier Princesse Grace
Conditions:
COVID-19
FDG PET/CT
Eligibility:
All Genders
18-99 years
Brief Summary
The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. Patients admitted with COVID-...
Detailed Description
\[18F\]-2-fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with increased anaerobic glycolysis seen...
Eligibility Criteria
Inclusion
- Patients were included if COVID-19 was confirmed according to the WHO guidance (11) by a positive result of RT-PCR assay of nasal and pharyngeal swabs, if they were hospitalized during the time period from day 6 to day 14 of the onset of symptoms, and if their initial (on admission) chest CT-scan presented ground-glass opacities (GGO) or consolidation.
Exclusion
- Patients could not be included if their medical condition was unstable or precluded a safe transfer to the nuclear medicine department, if they were under mechanical ventilation (either non-invasive or invasive), if they were initially referred to the critical care unit, and in case of a pregnancy.
Key Trial Info
Start Date :
March 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 27 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04441489
Start Date
March 27 2020
End Date
May 27 2020
Last Update
June 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Princesse Grace
Monaco, Monaco